manassantin-a and tetrahydrofuran

manassantin-a has been researched along with tetrahydrofuran* in 2 studies

Other Studies

2 other study(ies) available for manassantin-a and tetrahydrofuran

Article	Year
Evaluation of Manassantin A Tetrahydrofuran Core Region Analogues and Cooperative Therapeutic Effects with EGFR Inhibition. Journal of medicinal chemistry, 2020, 07-09, Volume: 63, Issue:13 Tumors adapt to hypoxia by regulating angiogenesis, metastatic potential, and metabolism. These adaptations mediated by hypoxia-inducible factor 1 (HIF-1) make tumors more aggressive and resistant to chemotherapy and radiation. Therefore, HIF-1 is a validated therapeutic target for cancer. In order to develop new HIF-1 inhibitors for cancer chemotherapy by harnessing the potential of the natural product manassantin A, we synthesized and evaluated manassantin A analogues with modifications in the tetrahydrofuran core region of manassantin A. Our structure-activity relationship study indicated that the α,α'- Topics: ErbB Receptors; Furans; HEK293 Cells; Humans; Lignans; Protein Kinase Inhibitors	2020
Analysis of HIF-1 inhibition by manassantin A and analogues with modified tetrahydrofuran configurations. Bioorganic & medicinal chemistry letters, 2009, Jul-15, Volume: 19, Issue:14 We have shown that manassantin A downregulated the HIF-1alpha expression and inhibited the secretion of VEGF. We have also demonstrated that the 2,3-cis-3,4-trans-4,5-cis-configuration of the tetrahydrofuran is critical to the HIF-1 inhibition of manassantin A. Topics: Animals; Cell Line; Furans; Hypoxia-Inducible Factor 1; Lignans; Mice; Vascular Endothelial Growth Factor A	2009

Article

Year

Evaluation of Manassantin A Tetrahydrofuran Core Region Analogues and Cooperative Therapeutic Effects with EGFR Inhibition.

Journal of medicinal chemistry, 2020, 07-09, Volume: 63, Issue:13

Tumors adapt to hypoxia by regulating angiogenesis, metastatic potential, and metabolism. These adaptations mediated by hypoxia-inducible factor 1 (HIF-1) make tumors more aggressive and resistant to chemotherapy and radiation. Therefore, HIF-1 is a validated therapeutic target for cancer. In order to develop new HIF-1 inhibitors for cancer chemotherapy by harnessing the potential of the natural product manassantin A, we synthesized and evaluated manassantin A analogues with modifications in the tetrahydrofuran core region of manassantin A. Our structure-activity relationship study indicated that the α,α'-

Topics: ErbB Receptors; Furans; HEK293 Cells; Humans; Lignans; Protein Kinase Inhibitors

2020

Analysis of HIF-1 inhibition by manassantin A and analogues with modified tetrahydrofuran configurations.

Bioorganic & medicinal chemistry letters, 2009, Jul-15, Volume: 19, Issue:14

We have shown that manassantin A downregulated the HIF-1alpha expression and inhibited the secretion of VEGF. We have also demonstrated that the 2,3-cis-3,4-trans-4,5-cis-configuration of the tetrahydrofuran is critical to the HIF-1 inhibition of manassantin A.

Topics: Animals; Cell Line; Furans; Hypoxia-Inducible Factor 1; Lignans; Mice; Vascular Endothelial Growth Factor A

2009